I don't understand the bashing of this 13d group
Post# of 153818
(Total Views: 530)
Posted On: 05/31/2021 11:49:37 AM
Re: Goosebumps #92411
I don't understand the bashing of this 13d group
I will admit up front that I do know a small number of shareholders within this group.
I don't understand the idea that because they have not shared any plans for the future(less than 1 week from filinig a 13d) that they have no plans. Clearly, they have significant concerns about the effectiveness of management and they have begun a professional process to share those concerns and will suggest alternatives that could help Leronlimab reach it's full potential. Management and all other shareholders will have the chance to review these concerns and alternatives and decide on the best path forward. Isn't this how shareholders should proceed if there are signifcant concerns about the management of a public company?
Of course, we all wish that the company would have acheived some of the clinical and regulatory milestones it has set for itself over the past 24 months and longer but we have reached a point where a signficant number of shareholders doubt whether the current management team has the necessary skills and experiences to advance the company foward. I wish that wasn't the case and our failure to advance Leronlimab was due alone to the influence of Big Pharma and FDA bias but I personally believe there is more do it than that. So I think it is reasonable for shareholders to consider alternatives.
Are are just a few of my own randon thoughs.
1. I think bringing any hint of disunity to CYDY was just about the last thing these 13d members wanted to do. I belive many of them(I can't speak for all) have really tried very hard to support Nader and management for many years. They have been as optimistic as the rest of us, that we could acheive clear success in our trials and earn EUA approval. It simply hasn't happened. I know many of them believed that the HIV BLA would be approved in 2020. Today statements from management make me feel that the BLA is as far from being approved as it has ever been. That is just my opinion, I could be wrong. We hired someone to help us acheive approvals in both these areas but he is no longer with us. If you are being objective, it is hard to see that the company has the needed experience and skills to move any approvals forward. Again, I could be totally wrong, but I don't understand how you could bash other shareholders for being seriously concerned about these failues of management.
2. Any vote for new directors to the board will likely not happen for a few months. The management team has the opportunity to continue forward with their plans. I hope that they are successful in some of their efforts to produce statistically significant study results that show LL effectiveness against Covid that can lead to an approval somewhere and revenue. Or to move the HIV BLA closer to approval. Every CYDY shareholder will be thrilled if they can but it would seem wise to begin the process to consider some different leadership for the future of CYDY.
I totally respect those that choose to support management but this board has usually been a place for serious discussion and I think it is wise for all shareholders to take the time to properly review and consider all proposals that come from either management or various shareholder groups over the coming weeks.
Each shareholder will have to decide what they think is best for the future of this amazing molecule.
This will be a marathon process not a sprint. Unless the company can acheive significant trial results or receive an approval, the stock price is probably going to remain under pressure for a while. The only thing that can change that is a clinical or regulatory accomplishment. Just my opinion, GLTA
I will admit up front that I do know a small number of shareholders within this group.
I don't understand the idea that because they have not shared any plans for the future(less than 1 week from filinig a 13d) that they have no plans. Clearly, they have significant concerns about the effectiveness of management and they have begun a professional process to share those concerns and will suggest alternatives that could help Leronlimab reach it's full potential. Management and all other shareholders will have the chance to review these concerns and alternatives and decide on the best path forward. Isn't this how shareholders should proceed if there are signifcant concerns about the management of a public company?
Of course, we all wish that the company would have acheived some of the clinical and regulatory milestones it has set for itself over the past 24 months and longer but we have reached a point where a signficant number of shareholders doubt whether the current management team has the necessary skills and experiences to advance the company foward. I wish that wasn't the case and our failure to advance Leronlimab was due alone to the influence of Big Pharma and FDA bias but I personally believe there is more do it than that. So I think it is reasonable for shareholders to consider alternatives.
Are are just a few of my own randon thoughs.
1. I think bringing any hint of disunity to CYDY was just about the last thing these 13d members wanted to do. I belive many of them(I can't speak for all) have really tried very hard to support Nader and management for many years. They have been as optimistic as the rest of us, that we could acheive clear success in our trials and earn EUA approval. It simply hasn't happened. I know many of them believed that the HIV BLA would be approved in 2020. Today statements from management make me feel that the BLA is as far from being approved as it has ever been. That is just my opinion, I could be wrong. We hired someone to help us acheive approvals in both these areas but he is no longer with us. If you are being objective, it is hard to see that the company has the needed experience and skills to move any approvals forward. Again, I could be totally wrong, but I don't understand how you could bash other shareholders for being seriously concerned about these failues of management.
2. Any vote for new directors to the board will likely not happen for a few months. The management team has the opportunity to continue forward with their plans. I hope that they are successful in some of their efforts to produce statistically significant study results that show LL effectiveness against Covid that can lead to an approval somewhere and revenue. Or to move the HIV BLA closer to approval. Every CYDY shareholder will be thrilled if they can but it would seem wise to begin the process to consider some different leadership for the future of CYDY.
I totally respect those that choose to support management but this board has usually been a place for serious discussion and I think it is wise for all shareholders to take the time to properly review and consider all proposals that come from either management or various shareholder groups over the coming weeks.
Each shareholder will have to decide what they think is best for the future of this amazing molecule.
This will be a marathon process not a sprint. Unless the company can acheive significant trial results or receive an approval, the stock price is probably going to remain under pressure for a while. The only thing that can change that is a clinical or regulatory accomplishment. Just my opinion, GLTA
(10)
(2)